Praxis precision medicines to present at guggenheim nantucket therapeutics conference

Boston, sept. 21, 2022 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the guggenheim nantucket therapeutics conference on wednesday, september 28, 2022 at 11:45 a.m. et.
PRAX Ratings Summary
PRAX Quant Ranking